Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Big Drugmakers Push Deeper Into Cancer Treatment -- 3rd Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2019 | 04:23pm EST

By Jared S. Hopkins and Denise Roland

Two of the world's biggest drugmakers struck multibillion-dollar deals on Monday aimed at bolstering their lineups in the fiercely competitive cancer-drugs market.

Merck & Co. said it would acquire ArQule Inc. for about $2.7 billion, paying a 107% premium in a bid to diversify its cancer treatments beyond top-selling drug Keytruda. Meanwhile, Sanofi SA said it would spend $2.5 billion, a 172% premium, to acquire Synthorx Inc. in the French drugmaker's own effort to catch up with rivals in the field of oncology.

Both deals reflect the industry's intense pursuit of new products to sell in one of the world's biggest and fastest-growing prescription-drug segments. The $123 billion world-wide cancer-drugs market is expected to almost double by 2024, according to market-research firm EvaluatePharma.

Bristol-Myers Squibb Co. recently closed on its $74 billion acquisition of rival Celgene Corp. to create a cancer-drugs powerhouse. Pfizer Inc., which has positioned itself as a company focused on cancer, bought Array BioPharma for $10.6 billion this summer. And Eli Lilly & Co. acquired Loxo Oncology for about $8 billion earlier this year.

The promise of new sales in a lucrative market appeals to pharmaceutical companies, which are counting on cancer treatments to provide new revenues as older products lose patent protection.

Making the segment even more attractive is the U.S. Food and Drug Administration's willingness to approve new cancer drugs with smaller, faster and less-expensive clinical trials. And companies have found that health plans will pay for cancer drugs, even at prices that often top $100,000 for a year's treatment.

Scientific breakthroughs, including the ability to target specific mutations and combine medicines, are also helping drive the industry's interest, said Roy Baynes, Merck's senior vice president of global clinical development and chief medical officer.

"The science is evolving very rapidly," Dr. Baynes said in an interview. "The good news is that we are now focused on drugs which really do have big effect."

But the interest in finding the next big new product has driven up the prices that big drugmakers have had to pay. Companies have paid mean premiums of 114% this year for small- to midsize deals such as Sanofi's and Merck's, up from 67% during the previous five years, according to analysts at Evercore ISI. The data are for drugs of all stripes, not just cancer treatments.

And the commercial market for cancer treatments has become hard-fought, forcing companies to race to be the first or second to market to secure a position before rivals.

Merck agreed to pay $20 a share in cash for ArQule, of Burlington, Mass. The deal is expected to close early in the first quarter of 2020.

It would increase Merck's offerings of therapies that treat blood-related cancers. ArQule's lead experimental treatment, called ARQ 531, is being tested in patients with blood cancers who carry a specific genetic mutation that prevented them from responding to previous treatments.

"It's early, but it looks like it has a lot of potential," Dr. Baynes said of the therapy.

Dr. Baynes acknowledged that other companies are developing therapies similar to ArQule's, but such contests drive innovation.

Merck has been looking for deals to expand its portfolio of cancer treatments beyond Keytruda, as some investors and analysts have worried that Merck has become too dependent on the product. Keytruda's global sales totaled nearly $7.2 billion last year.

Earlier this year, Merck, of Kenilworth, N.J., bought Tilos Therapeutics Inc. and Peloton Therapeutics Inc., both of which are developing cancer therapies.

Citigroup analysts said Merck's expansion in hematology makes sense because it hasn't been very active in that field, and expects the deal "to be the beginning rather than the end of similar moves."

Many of the therapies that big drugmakers are acquiring are immunotherapies such as Keytruda or complement the drugs, a relatively new class of treatment that unleashes a patient's own immune system in the fight against cancer.

For Sanofi, acquiring Synthorx, of La Jolla, Calif., is an attempt by the French pharmaceutical company to erase the gap with rivals that already sell the drugs. Synthorx's lead agent is in the early phase of patient testing in a range of cancers, both on its own and in combination with existing cancer immunotherapies.

The deal is the first big move by Sanofi Chief Executive Paul Hudson, who began leading the company in September, and suggests that cancer treatment will be one of the company's new priorities.

Sanofi said it would pay $68 a share in cash for Synthorx.

"This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation," Mr. Hudson said.

Sanofi is one of the most diversified companies in the industry, spanning branded prescription drugs, vaccines and over-the-counter treatments. Within branded drugs, it produces medicines ranging from insulin for diabetes to specialty medicines for rare diseases.

Write to Jared S. Hopkins at jared.hopkins@wsj.com and Denise Roland at Denise.Roland@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ARQ GROUP LIMITED 1.37% 0.37 End-of-day quote.-2.63%
ARQULE, INC. 0.15% 20 Delayed Quote.0.20%
BRISTOL-MYERS SQUIBB COMPANY -0.51% 63.83 Delayed Quote.-0.05%
CELGENE 0.10% 108.24 Delayed Quote.68.89%
CITIGROUP INC. -2.47% 76.4465 Delayed Quote.-1.84%
EVERCORE INC. -2.12% 73 Delayed Quote.-0.17%
MERCK AND COMPANY 0.42% 86.35 Delayed Quote.-5.46%
MERCK KGAA -2.00% 117.6 Delayed Quote.13.91%
PFIZER 0.24% 39.9 Delayed Quote.1.63%
PROCTER & GAMBLE COMPANY 0.82% 126.1041 Delayed Quote.0.19%
SANOFI -2.70% 86.7 Real-time Quote.-0.57%
SYNTHORX, INC. 0.00% 67.99 End-of-day quote.-2.72%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09:04aMerck KGaA Will Invest EUR250 Million in New Swiss Facility
DJ
07:18aMerck's Drug Approved for Diarrhea Treatment in Children
DJ
06:46aMERCK AND : FDA Approves Merck's DIFICID® (fidaxomicin) to Treat Clostridioides ..
BU
01/23BRIACELL THERAPEUTICS : Invited to Present at Mount Sinai's Frontiers in Academi..
AQ
01/23Merck Gets Canada OK for Keytruda/Inlyta Combo in Renal Cell Carcinoma
DJ
01/23MERCK AND : Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treat..
AQ
01/22MERCK AND : - FDA Accepts Regulatory Submission of Supplemental New Drug Applica..
AQ
01/22MERCK AND : FDA Accepts Regulatory Submission of Supplemental New Drug Applicati..
AQ
01/21Nigeria's booming market for hypertension care
AQ
01/21Myriad Submits sPMA for BRACAnalysis CDx Test
DJ
More news
Financials (USD)
Sales 2019 46 818 M
EBIT 2019 16 276 M
Net income 2019 9 957 M
Debt 2019 18 828 M
Yield 2019 2,59%
P/E ratio 2019 22,5x
P/E ratio 2020 18,0x
EV / Sales2019 5,08x
EV / Sales2020 4,75x
Capitalization 219 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 99,83  $
Last Close Price 85,98  $
Spread / Highest target 24,4%
Spread / Average Target 16,1%
Spread / Lowest Target 7,00%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-5.46%218 904
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG3.03%284 454
PFIZER1.63%220 369
NOVARTIS-0.38%213 484
BRISTOL-MYERS SQUIBB COMPANY-0.05%150 403